Geratherm Medical (GME) AI Stock Analysis

• Market Cap: €19.77M
• Dividend Yield: 2.93%
• Average Volume (3M): 4.33K
• Price to Earnings (P/E): 11.1
• Beta (1Y): 0.73
• Revenue Growth: -23.48%
• EPS Growth: N/A
• Country: DE
• Employees: 179
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.03
• Shares Outstanding: 5,444,998
• 10 Day Avg. Volume: 3,658
• 30 Day Avg. Volume: 4,334
• PEG Ratio: -0.70
• Price to Book (P/B): 0.90
• Price to Sales (P/S): 0.92
• P/FCF Ratio: 15.36
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 63 Neutral
• Price Target: €4.00 ▲(3.09% Upside)

Geratherm Medical's overall stock score reflects a balanced view of its financial stability, technical indicators, and attractive valuation. The strong balance sheet and improving cash flow are positive factors, while the declining revenue growth presents a challenge. Technical analysis suggests potential for a rebound, and the valuation metrics indicate the stock may be undervalued. The absence of earnings call and corporate events data limits additional insights.

Geratherm Medical Business Overview & Revenue Model

Company Description

Geratherm Medical (GME) is a global leader in the development and manufacturing of innovative medical devices, primarily focused on temperature measurement and monitoring solutions. The company operates in various sectors including healthcare, pharmaceuticals, and research, and offers a range of core products such as thermometers, blood pressure monitors, and diagnostic devices designed for both professional medical use and consumer markets.

How the Company Makes Money

Geratherm Medical generates revenue through the sale of its medical devices and diagnostic products to hospitals, clinics, and retail pharmacies. The company has established key revenue streams through direct sales, distribution agreements, and partnerships with healthcare providers and organizations. Additionally, GME focuses on expanding its market presence in emerging economies and leverages research and development to innovate and introduce new products, thus enhancing its competitive edge and driving sales growth.

Geratherm Medical Financial Statement Overview

Summary

Geratherm Medical demonstrates a mixed financial performance. The income statement highlights profitability challenges with declining revenue growth, while the balance sheet shows financial stability with low leverage. The cash flow statement indicates improving cash generation. The company needs to address revenue growth issues while maintaining its strong balance sheet and improving cash flow conversion.

Income Statement

Geratherm Medical's income statement shows a mixed performance. The TTM (Trailing-Twelve-Months) data indicates a decline in revenue growth rate by 109.5%, which is concerning. However, the company maintains a positive net profit margin of 12.27%, indicating profitability despite revenue challenges. The gross profit margin has decreased over time, reflecting potential cost management issues. Overall, the income statement reflects moderate profitability with significant revenue growth challenges.

Balance Sheet

The balance sheet of Geratherm Medical is relatively strong, with a low debt-to-equity ratio of 0.126 in the TTM, indicating prudent leverage management. The return on equity is modest at 8.38%, suggesting efficient use of equity to generate profits. The equity ratio remains stable, showing a solid equity base. Overall, the balance sheet reflects financial stability with low leverage and moderate returns on equity.

Cash Flow

Geratherm Medical's cash flow statement shows a positive trajectory in free cash flow growth at 23.03% in the TTM, indicating improved cash generation. The operating cash flow to net income ratio is strong at 3.18, suggesting robust cash flow relative to net income. However, the free cash flow to net income ratio is slightly below 1, indicating that not all net income translates into free cash flow. Overall, the cash flow statement reflects improving cash generation with some areas for further enhancement.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.29M	20.43M	20.96M	25.85M	24.64M	27.47M
Gross Profit	5.96M	12.78M	6.27M	6.38M	16.32M	17.60M
EBITDA	-1.94M	2.95M	4.18M	3.37M	2.20M	4.35M
Net Income	1.75M	705.17K	1.11M	1.02M	122.23K	2.05M
Balance Sheet
Total Assets	27.53M	28.54M	35.72M	38.38M	34.56M	35.99M
Cash, Cash Equivalents and Short-Term Investments	9.61M	9.64M	7.74M	10.89M	6.47M	10.26M
Total Debt	2.62M	3.28M	7.23M	9.29M	9.32M	10.40M
Total Liabilities	6.95M	7.71M	13.11M	16.15M	15.93M	16.07M
Stockholders Equity	20.83M	21.02M	22.33M	22.34M	18.52M	20.30M
Cash Flow
Free Cash Flow	2.68M	1.23M	-212.00K	-133.00K	-353.00K	1.14M
Operating Cash Flow	2.79M	1.87M	1.43M	2.61M	917.00K	3.92M
Investing Cash Flow	3.89M	3.82M	-2.09M	-767.00K	3.00K	-3.79M
Financing Cash Flow	-2.43M	-2.69M	-3.09M	4.35M	-3.52M	684.00K

Geratherm Medical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.88
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:GME, the sentiment is Negative. The current price of 3.88 is below the 20-day moving average (MA) of 4.44, above the 50-day MA of 3.63, and above the 200-day MA of 3.32, indicating a neutral trend. The MACD of -0.06 indicates Positive momentum. The RSI at 41.08 is Neutral, neither overbought nor oversold. The STOCH value of 11.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:GME.

Geratherm Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GME	63 Neutral	€19.77M	11.14	8.35%	2.93%	-23.48%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AAQ1	45 Neutral	€20.86M	―	-34.28%	―	-0.59%	24.03%